Advertisement

Topics

Companies Related to "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" [Most Relevant Company Matches] - Page: 3 RSS

18:44 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Trial Gemcitabine Carboplatin With Without PARP1 Inhibitor Patients" Companies 51–75 of 4,400+

Relevant

Impact Biomedicines

Impact Biomedicines (“Impact”) is pioneering the development of life changing treatments for patients with complex cancers. The Company’s pipeline is centered around fedratinib, a potent and highly selective oral small molecule, JAK2 kinase inhibitor that is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera ...


Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Prote...

VitalTrax

At VitalTrax connect, our mission is to enable patients to participate in clinical trials. Wing (www.patientwing.com) is a clinical trial network that allows patients to find and enroll in clinical trials. For more information, please visit vitaltrax.net.


Calistoga Pharmaceuticals, Inc.

Calistoga Pharmaceuticals is dedicated to developing targeted therapy to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting isoforms of the PI3K pathway. The Company’s most advanced compound, CAL-101, a selective PI3K delta inhibitor, is under c...

Probably Relevant

CleverCap

CleverCap® is a medication adherence platform designed for clinical trial professionals in order to manage adherence and the data associated with participant compliance, trial reporting and analysis. The CleverCap device-enabled medication adherence solution helps patients take the right dose, at the right time, combined with alerts, tracking, third-par...

Argonauta Communications

Argonauta Communications is certified as a women's business enterprise through the Women's Business Enterprise National Council (WBENC). We provide support for clinical trial recruitment and specialize in leading patients to treatment options. Clients utilize Argonauta Communications because of our high quality of service, customized approach, and attention to detail. We develop clinical trial...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Serametrix Corporation

Serametrix provides solutions to the problem of monitoring immune response to immunotherapies in clinical trial cancer patients. In partnership with leading institutes Serametrix has developed a suite of immunoassays that monitor anti-tumor immunity in patients enrolled into clinical trials for novel cancer therapies. Serametrix is part owned by the LICR. ...

Imara Inc.

Imara Inc., a Cydan Development company, is dedicated to developing novel therapeutics for patients with sickle cell disease. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. The company was launched following an 18-month diligence and de-risking scientific collabor...

Corautus Genetics

Corautus Genetics is dedicated to the clinical development of new therapies for the treatment of patients with serious diseases, including severe cardiovascular and peripheral vascular disease. Our goal is to become a world leader in introducing genetic therapy products into medical practice. In the Fall of 2004, Corautus initiated the largest trial of its kind in the United States for angina pati...

Quantum Clinical Research

Global Clinical Trial/Project Management Therapeutic Specialization Phase I Clinical Trial Mgmt Capabilities Phase II-III Capabilities Phase IIIb –IV Capabilities Post marketing Surveillance Treatment IND & Compassionate Use Regulatory Operations & QA Capabilities Worldwide Drug Safety Clinical Trial Monitoring CRA/Monitor Training Select Biometrics Capabilities

Cypress Bioscience

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications....

Callisto Pharmaceuticals, Inc.

Callisto Pharmaceuticals, Inc., is a publicly traded biotechnology company on the American Stock Exchange (AMEX:KAL) and Frankfurt Exchange (CA4). Callisto's primary focus is the clinical development of two drugs to treat cancer, L-Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma (MM) and bone resorption. L-Annamycin, a drug from the anthracycline family, earlier complet...

Nextrials, Inc

Nextrials is an innovative, award-winning, ileader in web-based software solutions for the clinical research industry. Prism®, the Company’s clinical trial management software, brings together sophisticated trial management and electronic data capture (“EDC”) in a single package enabling clinical researchers to derive more value from trial data, accelerate time to market and substantially l...

Clinical Research Associate

Clinical Research Associate, also known as a Monitor, is an individual that oversees the progress and conduct of a clinical trial. A clinical trial is usually implemented by physicians at a hospital, clinic, or physician's office. The CRA is required to oversee the initiation, progress, and conduct of the clinical trial to ensure the scientific integrity of the data collected, and the protection o...

Nereus Pharmaceuticals, Inc.

Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched expertise in marine microbiology to identify unique biologically active compounds, Nereus has two oncology drug candidates in clinical trials. Plinabulin (NPI-2358), a novel vascular disrupting agent, is being evaluated in patien...

Acceleron Pharma, Inc.

Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique ins...

Italfarmaco

Italfarmaco is a specialty pharmaceutical company engaged in the discovery, development, manufacturing and marketing of branded prescription and nonprescription products in more than 60 countries on 5 continents. Italfarmaco’s research and development expertise is best demonstrated through its HDAC inhibitor development programs, some of which are foc...

Excel PharmaStudies Inc.

Top leading contract research organization (CRO) in China. We could provide a full range of services including: product registration, conducting clinical trial and global trial, as well as statistic analysis and data management.

Slope.io

Slope.io is a clinical trial supply chain logistics company. The company uses a modern, data-driven technology platform with predictive analytics to enable patient-centered, automated and end-to-end integrated services for clinical trial supplies. Trial data powers automated, just-in-time delivery of clinical supplies to study sites. For more information, ...

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

Apexian Pharmaceuticals

Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs. Apexian’s lead drug candidate APX3330, is an oral first-in-class novel inhibitor of the APE1 protein, a critical node in cancer cell signaling. To learn more about Apexian Pharmaceuticals, pleas...

TransPerfect Trial Interactive

TransPerfect Life Science Solutions provides leading web-based platforms, including eTMFs, that enable sponsors, CROs, IRBs, central laboratories and other vendors to maintain and update clinical trial documentation in a secure online collaborative environment. The Trial Interactive platform enables fully searchable solutions including eTMFs and investigat...

Clinical Research Advantage, Inc.

Tempe, Ariz.-based Clinical Research Advantage, Inc. (CRA) is a provider of a range of research services to pharmaceutical companies and clinical research organizations (CROs). As a leading trial management organization (TMO), CRA operates from 29 sites across 12 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and e...

Novacea

We are a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. We currently have two clinical-stage oncology product candidates. Our lead product candidate, Asentar™ (DN-101), is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer, or AIPC, also known as hormone-refractory prostate cancer. ...


More From BioPortfolio on "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks